

Takafumi Yanagisawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5941579/publications.pdf>

Version: 2024-02-01

28
papers

265
citations

1039406

9
h-index

1125271

13
g-index

29
all docs

29
docs citations

29
times ranked

111
citing authors

#	ARTICLE	IF	CITATIONS
1	Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?. <i>BJU International</i> , 2023, 131, 190-197.	1.3	13
2	Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2022, 82, 3-12.	1.2	9
3	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	1.1	11
4	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	1.0	19
5	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	2.0	11
6	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.2	26
7	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124.	2.6	6
8	Residue and recurrence in percutaneous cryoablation for cT1 renal tumor: Clinical utility and feasibility of salvage cryoablation with iodized oil marking. <i>International Journal of Urology</i> , 2022, 29, 472-474.	0.5	4
9	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	1.6	10
10	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	1.7	13
11	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.0	6
12	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	2.0	7
13	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
14	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	1.0	10
15	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	0.4	2
16	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 315-330.	0.8	15
17	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	1.6	4
18	Feasibility and accuracy of pathological diagnosis in en bloc transurethral resection specimens versus conventional transurethral resection specimens of bladder tumour: evaluation with pT1 substaging by 10 pathologists. <i>Histopathology</i> , 2021, 78, 943-950.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2021, 16, 189-196.	1.7	3
20	Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer. <i>Journal of Urology</i> , 2021, 205, 1622-1628.	0.2	16
21	Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2021, 206, 252-259.	0.2	13
22	Performance of Indocyanine Green Fluorescence for Detecting Lymph Node Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 466.e1-466.e9.	0.9	9
23	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	1.1	5
24	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 479-485.	1.0	1
25	Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 938.e1-938.e7.	0.8	11
26	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. <i>World Journal of Urology</i> , 0, , .	1.2	3
27	Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study. <i>Prostate</i> , 0, , .	1.2	1
28	Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. <i>Prostate</i> , 0, , .	1.2	1